We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Diazyme develops diagnostic reagents using its proprietary enzyme technologies that can be used on most automated che... read more Featured Products: More products

Download Mobile App

Diazyme Obtains CE-IVD Marking for Its Semi-Quantitative SARS-CoV-2 Neutralizing Antibody Test

By LabMedica International staff writers
Posted on 05 Apr 2021
Print article
Diazyme Laboratories, Inc. (Poway, CA, USA) has obtained CE-IVD marking for its SARS-CoV-2 neutralizing antibody test, which is a high throughput chemiluminescent immunoassay with excellent correlation to a fluorescence based neutralization assay that has been used to evaluate the adaptive immune response in vaccine studies. Diazyme now plans to work with the US FDA for its EUA application.

“Unlike the widely available total SARS-CoV-2 IgG antibody tests, Diazyme’s neutralizing antibody test measures the subset of neutralizing antibodies that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein and the human ACE2 cell surface receptor. The Diazyme neutralizing antibody test gives the scientific community and health authorities a valuable tool to evaluate the level of effective antibodies generated after infection or vaccination, and to assess adaptive immunity in studies going forward. Diazyme serology tests meet real world expectations from healthcare professionals and have been independently evaluated in several published studies2-4,” said Dr. Chong Yuan, Managing Director of Diazyme Laboratories, Inc.

Gold Supplier
Respiratory Panel with SARS-CoV-2
BioFire Respiratory 2.1-EZ (RP2.1- EZ) Panel With SARS-CoV-2
SARS-CoV-2 PCR Assay
AppliedBiosystems TaqCheck SARS-CoV-2 Fast PCR Assay Kit
Gold Supplier
SARS-CoV-2, Flu A/B, and RSV Test
Gold Supplier
SARS-CoV-2 Antibody Test

Print article
BIOHIT  Healthcare OY


Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more


view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.